Paolo Parente

Plain English
This study looked at the quality and quantity of biopsy samples taken during endoscopic procedures for patients with gastrointestinal (GI) cancers. Researchers reviewed 819 procedures and found that while most biopsies could diagnose cancer (96% for upper GI and 84% for lower GI), a significant number didn't meet guidelines for the minimum number of samples needed for accurate testing. Specifically, 41-43% of the procedures didn’t provide enough biopsies, and many samples contained too few tumor cells to be useful for personalized treatment plans. Who this helps: This benefits patients with GI cancers by ensuring they receive more effective and tailored treatment options.

Plain English
This study examined a rare condition called Doege-Potter Syndrome (DPS) in a 76-year-old man who experienced frequent low blood sugar (hypoglycaemia) due to a large solitary fibrous tumor (SFT) that produced a hormone affecting insulin levels. The tumor, measuring 205 x 190 x 169 mm, was successfully removed through surgery, after which the patient's blood sugar levels returned to normal. This finding is important because it shows how crucial it is to understand these tumors to improve surgery safety and management of blood sugar levels. Who this helps: This helps patients with Doege-Potter Syndrome and doctors managing their care.

Plain English
This study focused on improving how biopsies from patients with gastrointestinal tumors are handled and tested to ensure accurate treatment decisions. The researchers identified key issues such as sample management and variation in biomarker expression that can affect the reliability of test results, emphasizing the need for clear guidelines in testing and reporting. Following their recommendations could lead to better treatment outcomes and avoid unnecessary procedures for patients. Who this helps: Patients with gastrointestinal cancer who need precise and personalized treatment options.

Plain English
This study examined how well people with lung cancer reported their quality of life and how this was related to their medical outcomes and treatment value in Australia. Among 490 patients, about 49% filled out surveys about their health-related quality of life, revealing that better quality of life was linked to earlier cancer stages, fewer comorbidities, and receiving recommended treatments. The findings show that patients diagnosed earlier generally had better health outcomes and lower treatment costs, which emphasizes the need for early detection and proper treatment to improve care for lung cancer patients. Who this helps: Patients with lung cancer.

Plain English
This study looked at the long-term results of minimally invasive surgery (MIS) for treating non-small cell lung cancer (NSCLC), which makes up about 85% of lung cancer cases. The researchers found that patients who had video-assisted thoracoscopic surgery (VATS) or robotic-assisted thoracoscopic surgery (RATS) generally had similar or better survival rates compared to traditional open surgery, with VATS showing more impressive results for early-stage cancer. These findings are important because they suggest that MIS can be a safe and effective treatment option that helps patients recover faster with fewer complications. Who this helps: This research benefits lung cancer patients facing surgery options and their doctors.

Plain English
This study looked at a specific type of cancer caused by a genetic change called NRG1 fusion, which leads to the activation of certain growth signals that help cancer cells survive and grow. The researchers found that drugs targeting either the NRG1 protein or its receptors (HER3 and HER4) could potentially treat these cancers. These new therapies, which include different combinations of drugs, offer a personalized option that could improve outcomes for patients with NRG1 fusions. Who this helps: Patients with cancers that have NRG1 fusions.

Plain English
This study looked at how cancer can change over time by comparing the genetic makeup of small bowel adenocarcinoma (SBA) tumors and their spread to the peritoneum (the lining of the abdominal cavity). Researchers found that in four cases, the cancer in the peritoneum was genetically identical to the primary tumors, while in one case, the metastatic tumor developed a new mutation over time. This highlights that cancers can vary even within the same patient, stressing the importance of testing metastases again for better treatment decisions. Who this helps: Patients with small bowel adenocarcinoma and their doctors.

Plain English
This study looks at how to better connect hospitals with local health authorities to improve vaccination rates for frail adult patients. Over four years, researchers will use digital tools to identify patients who need vaccinations and invite them to schedule appointments. The study will measure how well this system works and how satisfied patients are, aiming to see improvements in vaccination coverage. Who this helps: This benefits frail patients who need vaccinations and healthcare providers working to keep them healthy.

Plain English
This study focuses on using liquid biopsies, which detect circulating tumor DNA (ctDNA) in the blood, for diagnosing and monitoring gastric cancer. It highlights that liquid biopsies are valuable tools because they reflect the complicated nature of tumors, allow real-time tracking of tumor changes, and can be used when obtaining tissue samples is difficult. However, despite their advantages, the adoption of liquid biopsies in everyday clinical practice has been slow. Who this helps: Patients with gastric cancer.

Plain English
This study looked at how artificial intelligence (AI) and high-resolution digital imaging can help predict microsatellite instability (MSI) in colorectal cancer, which is important for tailoring treatment for patients. Researchers found that using AI to analyze whole slide images could provide a more effective and cost-efficient way to assess MSI status compared to traditional methods that can be slow and inconsistent. This advancement matters because it could improve the decision-making process for treatments, especially for patients who may benefit from specific therapies, like immune checkpoint inhibitors. Who this helps: This helps patients with colorectal cancer and their doctors.

Plain English
This study looked at how a special blood test, known as "liquid biopsy," can help doctors predict how well patients with metastatic colorectal cancer (mCRC) will respond to a specific treatment that includes the drug cetuximab combined with chemotherapy. The researchers found that patients with tumors that had no mutations in certain genes had a better response rate of 78.1% compared to 54.5% for those with mutations. Additionally, patients without these mutations had a longer time without disease progression, averaging 12.35 months versus 8.68 months for those with mutations. Who this helps: This benefits patients with metastatic colorectal cancer who are receiving anti-EGFR therapies.

Plain English
This study focused on creating a clear classification system for neck dissections, which are surgical procedures done to remove lymph nodes and tissues from the neck, used to treat head and neck cancers. The SEORL-CCC group analyzed existing classification methods and established their own standard that divides neck dissections into two main types based on the approach (functional or radical) and the extent of the surgery (comprehensive or selective). This new system is important because it allows doctors worldwide to better compare surgical outcomes and improve treatment practices. Who this helps: This benefits doctors and surgeons treating patients with head and neck cancers.

Plain English
This study examined the presence of tissue damage in children with very early-onset inflammatory bowel disease (VEO-IBD), even when endoscopy—which looks inside the body—shows no visible problems. Researchers found that in 43% of cases considered endoscopically healthy, there were still signs of histologic damage, particularly in patients with monogenic diseases (MDs). This is important because it shows that endoscopic exams alone may miss issues, indicating a need for thorough testing in these patients. Who this helps: Pediatric patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at patients with specific types of gastrointestinal lesions that could potentially develop into cancer, known as indefinite for dysplasia (IND). Researchers analyzed 719 patients and found that the risk of these lesions progressing to cancer is higher for Barrett's esophagus (4.4 per 100 person-years) compared to gastric lesions (1.6 per 100 person-years). The study showed that certain factors, like the type of lesions and the staging of gastritis, can help predict which patients are at greater risk, highlighting the importance of monitoring and managing these patients more carefully. Who this helps: This information helps doctors in monitoring and treating patients with Barrett's esophagus and gastric lesions.

Plain English
This study looked at whether using smartwatches to set goals and provide feedback could increase physical activity among cancer survivors while they are hospitalized. It involved 24 participants, and while those who received the smartwatch intervention showed some improvement in mobility, they did not walk more steps or spend less time sitting compared to those who received standard care. This matters because improving physical activity in cancer survivors could enhance their recovery, but the low number of participants and unclear benefits highlight the need for better ways to conduct similar studies in the future. Who this helps: Patients recovering from cancer.

Plain English
This study looked at the effects of different treatments for patients with stage IIIA melanoma, a type of skin cancer. Researchers found that patients who received targeted therapy (dabrafenib and trametinib) had a two-year chance of staying cancer-free (recurrence-free survival) of 98.6%, compared to 79.3% for those who were treated with anti-PD-1 drugs and 84.3% for those who just monitored their condition without treatment. The study suggests that while stage IIIA melanoma has a modest risk of coming back, targeted therapy may be more effective than anti-PD-1 therapy or no treatment at all. Who this helps: This helps patients with stage IIIA melanoma and their doctors in choosing more effective treatment options.

Plain English
This study looked at how the expression of certain biomarkers differs between primary gastric cancers and their corresponding peritoneal metastases in patients. Researchers analyzed 74 cases and found that while most tumors showed low rates of HER2 overexpression (5.4%) and DNA mismatch repair deficiency (4.1%), a high percentage had PD-L1 present in 79.7% of cases. These findings highlight the differences in tumor characteristics, which may impact treatment decisions and the effectiveness of therapies for patients with advanced gastric cancers. Who this helps: This benefits doctors and patients with gastric cancer, especially those facing peritoneal metastases.

Plain English
This study looked at younger patients under 55 years old with metastatic castration-resistant prostate cancer (mCRPC) and compared their treatment and outcomes to older patients. Out of 915 patients studied, only 59 were younger patients, and while both groups received similar first-line treatments (about 19% of younger patients got docetaxel compared to 21% of older patients), younger patients were more likely to undergo three or more lines of therapy (37% vs. 23%). Overall survival rates were comparable for both groups, with younger patients living a median of 41.9 months compared to 35.1 months for older patients. Who this helps: This research benefits healthcare providers treating younger men with prostate cancer, helping them understand treatment patterns and outcomes.

Plain English
This study looked at different types of non-functioning duodenal neuroendocrine tumors (NF-Duo-NETs) and how the hormones they produce might relate to their behavior. Researchers analyzed 151 cases and found that the most common subtype was somatostatin-producing tumors (31%), which were larger and more aggressive compared to other types, with tumors often metastasizing to nearby tissues. Understanding these hormone profiles is important because they can help predict how aggressive a tumor may be, regardless of its size, which can guide treatment decisions. Who this helps: This helps doctors better assess and treat patients with non-functioning duodenal neuroendocrine tumors.

Plain English
This study looked at how doctors can decide when to give anti-PD-(L)1 therapies again to patients who have early-stage cancers that have come back after initial treatment. Clinicians from 10 countries agreed that retreatment should be guided by factors like how well the patient responded to the first treatment, how long ago it was completed, and any previous side effects experienced. They found that doctors think retreatment could be considered at least 3 to 6 months after stopping the first treatment, or 6 months after the cancer recurs. Who this helps: This helps patients with early-stage cancers who may need additional treatment after a relapse.

Plain English
This study looked at how artificial intelligence (AI) can help pathologists score important biomarkers in gastroesophageal cancers, which include different types of tumors. Researchers found that AI can improve scoring consistency and lessen the heavy workload for pathologists when evaluating biomarkers like PD-L1 and HER2. This is crucial because it might lead to faster and more accurate diagnoses, which can ultimately improve treatment decisions for patients. Who this helps: This helps patients with gastroesophageal cancers and the doctors treating them.

Plain English
This study looked at how the COVID-19 pandemic affected the diagnosis of autoimmune inflammatory rheumatic diseases (AIIRDs) in a large population of 6.5 million people in central Italy. While there was a drop in diagnoses in 2020, the rates rose significantly in the following years, showing a 22% increase in 2023 compared to before the pandemic. This increase was mainly seen in types of arthritis and systemic rheumatic diseases, indicating a possible link to COVID-19 and changes in healthcare access during the pandemic. Who this helps: This research benefits patients with autoimmune diseases and healthcare providers, as it highlights the need for ongoing diagnosis and treatment during and after health emergencies.

Plain English
This study looked at how well hospitals in Victoria, Australia, performed on key quality measures for treating lung cancer between 2016 and 2021, analyzing data from 12,121 newly diagnosed patients. The researchers found that the quality of care varied significantly, with some hospitals achieving quality goals only 2.1% of the time while others reached 90%. Notably, meeting these quality measures was linked to better survival rates for patients—up to a 67% reduction in risk of dying for most indicators. Who this helps: This benefits lung cancer patients by improving treatment quality and survival outcomes.

Plain English
This study looked at a program in Italy that aimed to get more children aged 2-6 years to receive flu vaccinations at their schools. Out of 2,424 eligible children, only 405 ended up getting vaccinated, which is about 16.7%. A significant part of this effort included not just the kids, but also their parents and school staff, who also participated in the vaccination campaign. Who this helps: This helps children, their families, and school communities improve their flu vaccination rates.

Plain English
This study looked at a rare form of cancer called stage IV small bowel adenocarcinoma (SBA) to see how certain proteins related to cancer treatment were expressed. They found that 11.5% of the tumors had a mismatch repair deficiency, 7.7% tested positive for HER2, and 40% had HER3 positivity, showing some differences in how these proteins appeared across tumors. These results are important because they highlight the need to check these biomarkers in SBA patients to improve treatment options, especially since there were differences between the primary tumors and their metastases. Who this helps: Patients with stage IV small bowel adenocarcinoma.

Plain English
This research paper examines how to test for certain genetic features (called microsatellite status) in gastrointestinal cancers, which can help match patients with the right immunotherapy treatments. The authors found that understanding whether a tumor has a deficiency in repairing its DNA (known as dMMR) is crucial, not just for colorectal cancer but also for other gastrointestinal cancers. Accurate testing for this condition can significantly improve treatment decisions and outcomes for patients. Who this helps: This helps patients with gastrointestinal cancers seeking effective treatment options.

Plain English
This study examined how well a specific test for homologous recombination deficiency (HRD) works in diagnosing high-grade serous ovarian cancer (HGSOC). Out of 147 patients tested, 77.2% received valid HRD analyses, and 42.8% of those tested were found to have a positive HRD score, indicating potential for treatment with certain drugs (PARP inhibitors). This matters because accurate HRD testing can help personalize treatment options, improving outcomes for patients with this cancer type. Who this helps: Patients with high-grade serous ovarian cancer and their doctors.

Plain English
This study looked at how well combining two types of tests—tissue biopsy and liquid biopsy—can help predict how well certain cancer treatments work for patients with metastatic colorectal cancer. Out of 156 patients, those without mutations showed a much higher overall response rate of 79.6% compared to 44.2% in patients with mutations, and they had longer progression-free survival (12.4 months versus 7.4 months). This research matters because it helps doctors identify which patients will most benefit from specific treatments, potentially improving outcomes for those with harmful cancer variations. Who this helps: This helps patients with metastatic colorectal cancer and their doctors in making better treatment decisions.

Plain English
This study looked at malignant colorectal polyps (MCPs), which are early-stage colon cancers often found during routine exams. The researchers focused on improving how these polyps are diagnosed and assessed, providing clear recommendations for doctors on how to identify high-risk cases. They emphasized the importance of a team approach in deciding on the best treatment, which can vary from follow-up to surgery. Who this helps: This helps doctors and healthcare teams who treat patients with colorectal cancer.

Plain English
This study looks at a specific type of rare lymphomas, called CD20-negative large B-cell lymphomas, which often present challenges for doctors in diagnosing and treating them. These aggressive lymphomas have poor outcomes with current treatments, and they typically show unusual patterns, including weak markers that make them harder to identify. Understanding how to recognize these lymphomas more accurately, including their unique features, is crucial for improving patient care. Who this helps: This helps doctors and patients facing difficult-to-diagnose lymphoma cases.

Plain English
This study looked at a specific type of stomach cancer associated with Epstein-Barr virus (EBV) in 35 patients. Researchers found that 94% of these cancers showed EBV in all tumor cells and that the cancer types were primarily linked to chronic stomach inflammation, with 69% displaying a form called carcinoma with lymphoid stroma. This research highlights a distinct group of EBV-associated gastric cancers with unique genetic changes and immune responses, which could help tailor treatment strategies. Who this helps: This benefits patients with EBV-related gastric cancer and their doctors by providing insights for better treatment options.

Plain English
This study looked at how well patients with small cell lung cancer (SCLC) in Victoria, Australia, received treatments that meet established guidelines. It found that 78.1% of the 1,769 patients studied got guideline-concordant treatment, while those who did benefit significantly, experiencing a 60% lower risk of dying compared to those who did not get this type of treatment. Understanding the barriers that prevent some patients, particularly older individuals and those with more advanced disease, from receiving the appropriate care is important for improving survival rates in SCLC. Who this helps: This helps patients with small cell lung cancer and their doctors.

Plain English
This study looked at colorectal cancer (CRC) and examined the genetic mutations that occur in tumors from over 2,800 patients across 12 medical centers. They found that nearly half (47.4%) of the patients had a specific mutation, with a notable prevalence among younger males and certain types of tumor characteristics. Understanding these mutations is important because they can influence treatment decisions and outcomes in patients with advanced cancer. Who this helps: This helps patients by providing insights that can lead to more personalized and effective treatment options.

Plain English
This study looked at how changes in DNA methylation can help detect and manage lung cancer. Researchers found that measuring these changes in cancer patients' blood samples could be a promising way to identify whether the cancer is resistant to treatments, including specific therapies that target cancer cells and immunotherapies. Although these findings are hopeful, more extensive testing is needed before these methods can be widely used in doctors' offices. Who this helps: Patients with lung cancer and their doctors can benefit from these advancements in detection and treatment monitoring.

Plain English
This study focused on improving cervical cancer screening by adding molecular HPV testing to traditional methods, using tissue samples from patients. Researchers analyzed 55 tissue samples and found that HPV DNA was present in 56.4% of them, with higher viral loads linked to more severe lesions. This new approach helps better identify patients at risk for developing cervical cancer, potentially reducing unnecessary follow-ups and overdiagnosis. Who this helps: This benefits patients at risk for cervical cancer and their doctors in making more accurate diagnoses.

Plain English
This study looked at how PD-L1 expression is measured in patients with esophageal and stomach cancers in Italy and compared those results to data from clinical trials. Researchers analyzed 1,936 cancer cases from 28 pathology centers and found that while most of the reported PD-L1 scores matched clinical trial findings, there was a significant variation between institutions—ranging from 43.6% to 100% of cases showing PD-L1 expression. This matters because understanding these differences helps improve the accuracy of patient evaluations for immune checkpoint inhibitor treatments, which can significantly extend survival. Who this helps: This helps patients with esophageal and gastric cancers by improving the selection process for effective treatments.

Plain English
This research paper looks at the connection between people being hesitant to get vaccinated and the resulting bone and joint problems caused by diseases that could have been prevented by vaccines. The findings indicate that low vaccination rates lead to increased cases of serious health issues, such as fractures and arthritis linked to diseases like measles and COVID-19. This is particularly concerning in older populations, as more people over 60 means more complications from these diseases, highlighting the urgent need for better vaccination efforts to protect overall bone health. Who this helps: This helps patients and healthcare providers, especially in regions with aging populations.

Plain English
This study focused on a protein called B7-H3, which is found on the surface of cells and might help cancer cells avoid the immune system, making them more aggressive. In a group of 87 patients with early colorectal cancer, researchers found that 76.5% had high levels of B7-H3, especially in a specific cancer type known as CRC, NOS, where the positivity rate reached 90.5% for low-grade cases. This research is important because understanding B7-H3's role could lead to new treatments that improve the effectiveness of immunotherapy for colorectal cancer patients. Who this helps: This helps patients with colorectal cancer and their doctors in developing better treatment strategies.

Plain English
This study looked at patients with advanced colorectal cancer who had been treated with a specific drug (anti-EGFR) and found that these patients had more genetic mutations in their tumors, particularly in the MAPK signaling pathway. Out of 559 patients analyzed, 33.8% of those who had previous anti-EGFR treatment had 10 or more mutations in their tumors, compared to just 9.7% of those who had not been treated with this drug. These results are important because they suggest that patients with high mutation levels after anti-EGFR therapy might benefit from new treatments like immunotherapy. Who this helps: Patients with advanced colorectal cancer who were previously treated with anti-EGFR drugs.

Plain English
This study looked at a rare case involving a 10-year-old boy who experienced painless rectal bleeding. Doctors found a 2 cm polyp in his rectum, which was removed, and the examination showed unusual bone-like tissue within the polyp. This finding is uncommon and, while it does not indicate any serious health risks, it contributes to our understanding of rare abnormalities in rectal polyps. Who this helps: This helps doctors better understand rare conditions in children.

Plain English
This research looked at how fecal microbiota transplantation (FMT), a treatment that involves using stool from a healthy donor to restore balance in the gut, might help with various gastrointestinal diseases, specifically inflammatory bowel disease (IBD), colitis caused by cancer treatments, and gastrointestinal graft-versus-host disease. The findings showed that FMT is showing promise as a potential treatment for these conditions, suggesting it could improve patients’ health outcomes but emphasizes that more research is needed to fully understand its effectiveness. This matters because these diseases can be very challenging to treat and effective new options can significantly benefit patients' quality of life. Who this helps: Patients suffering from these gastrointestinal diseases.

Plain English
This study looked at the effects of a medication called glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on diabetic patients undergoing surgery to relieve pressure on a nerve in their arm. The results showed that patients taking GLP-1 RAs had fewer emergency room visits (8.9% vs. 10.7%) shortly after surgery and a lower chance of needing a second surgery (5.2% vs. 6.9%) and developing ongoing nerve problems over two years (23.4% vs. 30.4%). These findings are important because they suggest that GLP-1 RAs may help diabetic patients recover better after this type of surgery. Who this helps: Diabetic patients undergoing cubital tunnel surgery.

Plain English
This study looked at the genetic changes (mutations) in lung cancer patients from Southern Italy who had their tumors surgically removed. Researchers found that 16% of the patients had changes in the gene, particularly in non-smoking and female patients, and 31.5% had mutations in the gene related to cancer. These findings are important because they provide more insight into how lung cancer behaves in this specific region, which can help guide future treatment options. Who this helps: This helps patients with lung cancer and their doctors.

Plain English
This study examined how DNA methylation, a process that can silence genes, affects a protein called SPARC in patients with idiopathic pulmonary fibrosis (IPF), a serious lung disease. Researchers analyzed tissue samples from 44 people with IPF and compared them to samples from 23 people without the disease. They found that 45% of the IPF samples showed increased methylation of the SPARC gene compared to only 13% of the control samples, suggesting that this methylation could serve as a potential marker for IPF. Who this helps: This research benefits patients with idiopathic pulmonary fibrosis by identifying a possible marker for the disease.

Plain English
This study looked at the genetic makeup of gastrointestinal stromal tumors (GISTs) in 31 patients using advanced DNA testing called Next Generation Sequencing (NGS). The researchers found that three patients had rare mutations in a specific part of a gene called KIT, which influence how well they respond to a common treatment called imatinib. This research is important because it shows how using NGS can help doctors better understand these tumors and tailor treatments for patients by identifying these uncommon genetic variations. Who this helps: This helps patients with GISTs and their doctors in making informed treatment decisions.

Plain English
This study focused on a group of cancers known as mucinous carcinomas, which have specific genetic changes involving a signaling pathway called NRG/ErbB. Researchers found that these cancers have more genetic mutations in important pathways compared to other types, with a notable increase in mutations related to the RAS/MAPK and PIK3K/AKT pathways. Understanding these patterns is important because they may help predict how aggressive the cancer is and guide treatment options. Who this helps: This helps patients with mucinous carcinoma and their doctors in making informed treatment decisions.